Recevez les dernières nouvelles sur l'action Silexion Therapeutics avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de SLXN

Dernières nouvelles pour

Silexion Therapeutics

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Earnings

News

Health Care

Markets

Press Releases

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Financing

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

SLXN

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aditxt

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Entero Therapeutics

Galecto

Genprex

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Oragenics

Onconetix

Palisade Bio

Polyrizon

PharmaCyte Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

SILO Pharma

Theriva Biologics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Comments

Silexion Therapeutics Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL